Vivenza D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, Comino A, Russi E, Lo Nigro C, Merlano M. Int J Biol Markers. 2016 Feb 17:0. doi: 10.5301/jbm.5000192. Abstract PURPOSE: Adequate biomarkers are still required to optimize therapy in patients with locally advanced head and neck squamous carcinomas (HNSCC) treated with chemoradiotherapy (CRT). […]
Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC. World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222. Abstract AIM: To investigate the prognostic role of invariant natural killer T (iNKT) cells and antibody-dependent cell-mediated cytotoxicity (ADCC) in wild type KRAS […]
Bozec A, Ebran N, Radosevic-Robin N, Sudaka A, Monteverde M, Toussan N, Etienne-Grimaldi MC, Nigro CL, Merlano M, Penault-Llorca F, Milano G. Laryngoscope. 2015 Nov 24. doi: 10.1002/lary.25754. [Epub ahead of print] Abstract OBJECTIVES/HYPOTHESIS: Recent preclinical and clinical studies on head and neck squamous cell carcinoma (HNSCC) revealed synergistic effects when combining anti-EGFR agents with […]
Merlano MC, Denaro N, Vivenza D, Monteverde M, Russi E, Lerda W, Comino A, Lo Nigro C. Int J Biol Markers. 2015 Oct 20:0. doi: 10.5301/jbm.5000175. [Epub ahead of print] Abstract BACKGROUND: p16 has been indicated as a suitable surrogate biomarker of HPV infection. The prognosis of p16-positive oropharynx tumors (OTs) of squamous cell carcinoma […]
Br J Cancer. 2015 Sep 15;113(6):970-8. doi: 10.1038/bjc.2015.302. Epub 2015 Sep 1. O’Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K, Lackner M, Wischnewsky MB, Crook T, Lo Nigro C, Schmid P. Abstract BACKGROUND: The transforming growth factor-beta (TGF- β) pathway has been implicated in proliferation, migration and […]
Int J Biol Markers. 2015 May 26;30(2):e208-16. doi: 10.5301/jbm.5000126. Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C. Abstract It is already well known that hypermethylation of the O6-methylguanine DNA methyltransferase (MGMT) gene promoter is […]
Anticancer Res. 2014 Dec;34(12):6887-96. Denaro N, Merlano MC, Russi EG, Lo Nigro C. Abstract BACKGROUND: Head and neck squamous cell carcinoma is a common cause of cancer death. Despite decades of clinical studies exploring new treatments and considerable advance in multimodality treatment, satisfactory curative rates have not yet been reached. In the last few decades […]
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G, Merlano M, Lo Nigro C. Invest New Drugs. 2015 Apr;33(2):310-20. doi: 10.1007/s10637-015-0210-1. Abstract Introduction In complement to anti-EGFR therapy, the targeting of PI3K/AKT/mTOR signaling pathway is […]
The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients. Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C. Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Abstract BACKGROUND: Advances in the understanding of tumor […]